| DIRECT COMPETITOR COMPARISON | |
| IMGN | IMMU | Pvt1 | SGEN | Industry | | Market Cap: | 465.04M | 255.64M | N/A | 943.99M | 100.26M | | Employees: | 210 | 120 | 4881 | 261 | 65 | | Qtrly Rev Growth (yoy): | -49.40% | 696.10% | N/A | 44.20% | 19.70% | | Revenue (ttm): | 24.96M | 64.14M | 52.30M1 | 40.26M | 14.05M | | Gross Margin (ttm): | -85.22% | 67.29% | N/A | -217.41% | 65.67% | | EBITDA (ttm): | -28.47M | 38.14M | N/A | -100.69M | -12.30M | | Oper Margins (ttm): | -134.15% | 57.13% | N/A | -258.38% | -137.11% | | Net Income (ttm): | -34.92M | 36.52M | -38.50M1 | -100.16M | N/A | | EPS (ttm): | -0.663 | 0.477 | N/A | -1.168 | -0.32 | | P/E (ttm): | N/A | 7.13 | N/A | N/A | 16.37 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.31 | | P/S (ttm): | 19.04 | 4.11 | N/A | 24.04 | 9.43 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.21 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | SGEN | | Seattle Genetics to get $12M from Agensys
Mon, Nov 23 -
at bizjournals.com | | • | SGEN | | Seattle Genetics gets $12 million in Astellas deal
Mon, Nov 23 -
AP | | • | SGEN | | SEATTLE GENETICS INC /WA Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh
Mon, Nov 23 -
EDGAR Online | | • | SGEN | | Seattle Genetics and Agensys, an Affiliate of Astellas, Expand Antibody-Drug Conjugate Collaboration
Mon, Nov 23 -
Business Wire | | • | SGEN | | Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75
Mon, Nov 16 -
Business Wire | | • | IMMU | | Piper Jaffray Senior Research Analyst Sees M&A Activity As Brisk As Foreign Companies Seek US Specialty Pharmaceutical Distribution Networks
Fri, Nov 13 -
Wall Street Transcript | | • | IMMU | | IMMUNOMEDICS INC Financials
Wed, Nov 11 -
EDGAR Online Financials | | • | IMMU | | UBS Research Equity Analyst Picks Top Stocks In Large Cap Biotech Sector
Tue, Nov 10 -
Wall Street Transcript | | • | IMMU | | New Star Analyst Rankings for Immunomedics, Inc.
Tue, Nov 10 -
StarMine | | • | IMMU | | IMMUNOMEDICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Fri, Nov 6 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
